TSCIP is an execution partner—not just an advisory layer.
For selected assets, TSCIP develops the counterparty thesis with the owner, takes that thesis into the field, engages relevant pharma teams one-on-one, returns de-identified decision requirements and uses those outputs to shape transaction readiness.
Why this matters.
An owner can have credible data and still struggle to get substantive responses from overloaded S&E teams. A theoretical target list does not solve that problem. TSCIP's role is to narrow the universe, make the strategic case relevant to each buyer, engage directly and learn what must change for the opportunity to advance.
The practical question
Can TSCIP obtain substantive engagement from a credible buyer universe—and, if not yet, what must change in the asset to make that possible?
Owner-facing deliverables.
Selective coverage
Admission only when TSCIP believes a credible counterparty thesis and field-engagement path exist.
Counterparty mapping
A focused buyer universe built around strategy, portfolio context, disease area and transaction logic.
One-on-one field BD
Targeted outreach to relevant S&E, External Innovation, BD and franchise teams using owner-authorized materials.
De-identified field intelligence
Evidence requirements, objections, diligence questions and conditions for advancement synthesized across engagement.
Evidence & development gate
The field-informed question the next evidence tranche should be designed to answer.
Qualified buyer access
Direct buyer-owner discussion when a counterparty elects to engage, plus Strategic Asset Review opportunities when warranted.
Capital-to-inflection
Capital requirements organized around the field-validated evidence milestone rather than generic runway.
Re-engagement
TSCIP returns to mapped counterparties when new evidence or a revised transaction proposition changes the discussion.
Transaction readiness
A continuously updated view of what is required for the asset to become actionable to credible counterparties.
Strategic Asset Reviews create qualified access—not pay-to-pitch access.
Small, buyer-specific, invitation-only.
When a buyer has reviewed TSCIP-covered opportunities and the fit warrants direct discussion, TSCIP may convene a focused review of a small slate—typically four to five pre-vetted assets presented sequentially by their owners. The buyer sees only opportunities selected against its own strategy and interests.
What TSCIP does not promise.
Coverage does not guarantee a licensing transaction, investment, meeting or inclusion in a buyer slate. Buyer access is earned through strategic fit and buyer interest. That selectivity is necessary for TSCIP to remain useful to both sides.